ARTICLE | Company News
Amgen launches osteoporosis drug at $21,900 per treatment course
April 19, 2019 12:23 AM UTC
Amgen launched Evenity romosozumab-aqqg in the U.S. at $1,825 per month to treat osteoporosis in postmenopausal women at high risk of fracture.
Amgen Inc. (NASDAQ:AMGN) said the list price for a full course of Evenity is 34-74% lower than currently available anabolic agents over their full course of therapy. Evenity costs $21,900 for a 12-month treatment course based on the supporting clinical trials on its U.S. label. ...
BCIQ Target Profiles